NDT Advance Access published online on April 4, 2006
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl146
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Nephrology, University of Skopje, Macedonia
* To whom correspondence should be addressed. Background. Lanthanum carbonate (LC) has been proposed as a new phosphate binder. Presented here are the results from one centre that participated in a multicentre trial to assess the effect of treatment with LC and calcium carbonate (CC) on the evolution of renal osteodystrophy in dialysis patients. Bone biopsies were performed at baseline, after 1 year of treatment and after a further 2-year follow-up period to assess the lanthanum concentration in bone and plasma. Methods. Twenty new dialysis patients were randomized to receive LC (median dose 1250 mg) for 1 year (n = 10), followed by 2 years of CC treatment or CC (n = 10) during the whole study period (3 years). Results. After 36 weeks of treatment, steady state was reached with plasma lanthanum levels varying around 0.6 ng/ml. Six weeks after cessation of 1 year of treatment, the plasma lanthanum levels declined to a value of 0.17 ± 0.12 ng/ml (P < 0.05) and after 2 years to 0.09 ± 0.03 ng/ml. Plasma and bone lanthanum levels did not correlate with the average lanthanum dose at any time point. The mean bone concentration in patients receiving LC increased from 0.05 ± 0.03 to 2.3 ± 1.6 µg/g (P < 0.05) after 1 year and slightly decreased at the end of the study to 1.9 ± 1.6 µg/g (P < 0.05). Conclusions. Bone deposition after 1 year of treatment with LC is low (highest concentration: 5.5 µg/g). There is a slow release of lanthanum from its bone deposits 2 years after the discontinuation of the treatment and no association with aluminium-like bone toxicity.
Received March 5, 2006
Accepted March 8, 2006
Original Article
Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up
Goce B. Spasovski 1 *,
Aleksandar Sikole 1,
Saso Gelev 1,
Jelka Masin-Spasovska 1,
Tony Freemont 2,
Isabel Webster 3,
Maggie Gill 3,
Chris Jones 3,
Marc E. De Broe 4,
and
Patrick C. D'Haese 4
2 Department of Osteoarticular Pathology, The Medical School, University of Manchester, UK
3 Shire Pharmaceuticals Group plc, Basingstoke, UK
4 Department of Physiopathology, Facutlty of Medicine, University of Antwerp, Belgium
Goce B. Spasovski, E-mail: gspas{at}sonet.com.mk
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. D. L. Smyth and R. D. Pratt A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report Nephrol. Dial. Transplant., October 5, 2009; (2009) gfp508v2. [Full Text] [PDF]
|
|
|
|
|
|
C. Muller, F. Chantrel, and B. Faller A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3245 - 3247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. L. Davis and J. L. Abraham Lanthanum deposition in a dialysis patient Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3247 - 3250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. P. How, D. L. Mason, and A. H. Lau Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder Journal of Pharmacy Practice, June 1, 2008; 21(3): 196 - 213. [Abstract] [PDF]
|
|